ClinicalTrials.gg
Status unknownNCT05537987Updated Jan 20, 2023

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ICP-723 in Advanced Solid Tumors, sponsored by InnoCare Pharma Inc.. Status unknown at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-20.

Sponsored by InnoCare Pharma Inc. · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jul 2021, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

During this study, dose escalation will be conducted in subjects with advanced solid tumors who have experienced treatment failure after clinical standard of care treatments or who currently have no effective treatment available to evaluate the safety, tolerability, and PK of ICP-723

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

InnoCare Pharma Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with histopathologically confirmed locally advanced malignant solid tumors that are unresectable or and that are unresponsive to standard treatments or have ; patients who have progressed under standard treatment including prior treatment with TRK or ROS1 inhibitors.
  2. Male or female patients with age ≥18 years old and ≤80 years old.
  3. according to 1.1.
  4. Adequate organ functions that meet protocol requirement criteria.
  5. Patients with asymptomatic, stable primary central nervous system (CNS) tumors or (treated or untreated)
  6. Participates voluntarily, signs , and follows the study treatment plan and scheduled visits.

Exclusion criteria

Exclusion Criteria:

  1. Other than the advanced malignant solid tumor under study, patients with another one or more active within the previous 5 years except for locally curable cancers that have been apparently cured
  2. Received systemic anti-cancer therapy including chemotherapy (except for oral fluorouracil chemotherapy), radiation therapy, hormones, targeted drugs, or biological immunotherapy within 4 weeks or 5 half-lives
  3. Major surgery (thoracotomy, laparotomy, etc.) within 4 weeks or minor surgery (superficial skin surgery, lymphadenectomy, hernia repair, etc.) within 2 weeks before the first dose of the study drug
  4. gastrointestinal/neurological dysfunction that may affect drug intake, transport, or absorption.
  5. Has evidence of uncontrolled heart disease
  6. At the investigator's discretion, evidence of severe or uncontrolled systemic disease.
  7. Other conditions considered by the investigator to be inappropriate for participation in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ICP-723

    Drug: ICP-723

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensity

    Time frame: through study completion, an average of 1.5 years.

Secondary outcomes

  1. Objective response rate (ORR) determined using RECIST 1.1 criteria.

    Time frame: Through study completion, an average of 4 years

  2. Disease control rate (DCR) determined using RECIST 1.1 criteria.

    Time frame: Through study completion, an average of 4 years

  3. Peak concentration (Cmax)

    Time frame: Through study completion, an average of 4 years

  4. Time to reach peak concentration (Tmax)

    Time frame: Through study completion, an average of 4 years

  5. Half-life (t1/2)

    Time frame: Through study completion, an average of 4 years

  6. Area under the plasma concentration-time curve (AUC0-∞ and AUC0-t)

    Time frame: Through study completion, an average of 4 years

  7. Apparent clearance (CL/F)

    Time frame: Through study completion, an average of 4 years

  8. Apparent volume of distribution (Vz/F),

    Time frame: Through study completion, an average of 4 years

07

Study locations

3 sites
  • University of Kansas Medical / Cancer Centers
    Kansas City, Kansas 66506, United States
  • NYU-Langone Medical Center
    New York, New York 10016, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Nov 2023, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2022
First posted
Sep 13, 2022
StartActual
Jul 30, 2021
Primary completionEst.
Nov 2023
CompletionEst.
Jul 2024
Last update
Jan 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05537987
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Jul 30, 2021
Primary completion
Nov 2023 (estimated)
Completion
Jul 2024 (estimated)
Last update
Jan 20, 2023

Study contacts

Jun Zhang
principal investigator · University of Kansas Medical / Cancer Centers

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zurletrectinib

Start the discussion